Atorvastatin Calcium Tablet
Product Images NDC 68071-2994

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 68071-2994). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2994 9)

Atorvastatin Calcium 40 mg tablets label from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 90 tablets with directions to see the manufacturer's label for a full list of ingredients. It includes manufacturer information for Graviti Pharmaceuticals Pvt. Ltd., Telangana, India and NuCare Pharmaceuticals, Inc., Orange, CA. Additional label elements include storage instructions, a barcode, and placeholders for lot, expiration date, and serial numbers.*

FDA Label Image

Image (Ab2e9c42 2421 421d B7c7 9539cb6dcb08 01)

Chemical structure diagram of atorvastatin calcium, showing its molecular arrangement and chemical bonds. The image details the composition including calcium ions and hydration molecules as part of the overall structure.*

FDA Label Image

Image (Ab2e9c42 2421 421d B7c7 9539cb6dcb08 02)

A line graph depicting the cumulative incidence (%) over time in years, comparing atorvastatin with placebo. The solid line represents atorvastatin while the dashed line represents placebo, showing a lower cumulative incidence for atorvastatin over approximately 3.5 years. The graph includes a hazard ratio (HR) of 0.64 with confidence intervals (0.50-0.83) and a p-value of 0.0005.*

FDA Label Image

Image (Ab2e9c42 2421 421d B7c7 9539cb6dcb08 03)

A line graph depicting cumulative hazard (%) over time (years) up to 5 years. It compares placebo and atorvastatin, showing a lower cumulative hazard for atorvastatin across the follow-up period, with a hazard ratio (HR) of 0.63 and p-value of 0.001 labeled on the graph.*

FDA Label Image

Image (Ab2e9c42 2421 421d B7c7 9539cb6dcb08 04)

A Kaplan-Meier curve showing the time to first major cardiovascular endpoint over 5 years for subjects taking atorvastatin 10 mg and 80 mg. The y-axis represents the percentage of subjects experiencing the event, and the x-axis shows time in years. The graph includes hazard ratio and p-value statistics comparing the two dosage groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.